The COVID-19 pandemic dealt a blow to Johnson & Johnson’s Vision Care business, but the company maintained its innovation program and kept customer engagement to the fore. It has started to see a return to positive contact lens buying trends, says Vision Care European business leaders Sandra Rasche and Lisa Ann Hill.
Early in the COVID-19 pandemic, Johnson & Johnson’s contact lens business leaders decided to set up regular consumer surveys to gauge the pandemic’s impact on contact lens usage during the lockdowns and quarantine periods. The surveys also allowed the Vision Care business to keep pace with public confidence changes, patients’ ongoing needs and buying habits.
Through its Acuvue portfolio, Johnson & Johnson is the global contact lens market leader, says Lisa Ann Hill, who is...
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.
Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
